Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
BlueRock Therapeutics was founded in 2016 when Versant Ventures, a top-tier venture capital firm, and global pharmaceutical giant Bayer AG provided $225 million in one of the largest-ever Series A financings in biotech history.Driven by a mission to develop regenerative medicines for intractable diseases, and initially focusing on the work of two McEwen Stem Cell Institute Scientists, BlueRock Therapeutics is advancing a novel Cell+Gene platform to develop, manufacture and deliver cell-based therapies.
The work of Dr. Gordon Keller and Dr. Michael Laflamme is part of BlueRock's first efforts to commercialize an approach to regenerating heart muscle in patients who have had a heart attack or suffer from chronic heart failure. The potential of cell therapy for regenerative medicines has been recognized for decades. However, the complexity of manufacturing cells that are suitable for use in patients at clinical scale has hindered development — until now. Using the latest in molecular biology technologies and manufacturing approaches, BlueRock is poised to overcome these hurdles.
Learn more about
BlueRock Therapeutics »
CCRM is a Canadian, not-for-profit funded by the Government of Canada, the Province of Ontario, and leading academic and industry partners. It supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. CCRM has a 40,000 square foot space dedicated to advanced cell manufacturing that includes a fully resourced development facility used to both evaluate and advance technologies. CCRM aims to accelerate the translation of scientific discovery into new companies and marketable products for patients. CCRM is the commercialization partner of OIRM and University of Toronto’s
Medicine by Design.
Learn more about
UHN and the Technion-Israel Institute of Technology have established a new Centre aimed at developing new ways to treat heart disease. By combining the efforts of the leading scientists and clinicians of Technion and UHN, this partnership, which includes UHN's McEwen Centre for Regenerative Medicine and the Peter Munk Cardiac Centre, will develop new cardiovascular devices and regenerative medicine therapies and innovations that will benefit not only Canadians and Israel but all patients suffering from cardiovascular disease across the globe. Moreover, the new Centre will support the training of the next generation of scientists and clinicians who will specialize in the continually growing fields of stem cell and regenerative medicine research.
Learn more about